Vera Hirsh

32.8k total citations · 12 hit papers
197 papers, 19.7k citations indexed

About

Vera Hirsh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Vera Hirsh has authored 197 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 166 papers in Pulmonary and Respiratory Medicine, 164 papers in Oncology and 30 papers in Molecular Biology. Recurrent topics in Vera Hirsh's work include Lung Cancer Treatments and Mutations (153 papers), Lung Cancer Research Studies (65 papers) and Colorectal Cancer Treatments and Studies (49 papers). Vera Hirsh is often cited by papers focused on Lung Cancer Treatments and Mutations (153 papers), Lung Cancer Research Studies (65 papers) and Colorectal Cancer Treatments and Studies (49 papers). Vera Hirsh collaborates with scholars based in Canada, United States and United Kingdom. Vera Hirsh's co-authors include Frances A. Shepherd, Tony Mok, James Chih‐Hsin Yang, Lesley Seymour, Andrea Bezjak, Tudor–Eliade Ciuleanu, Sumitra Thongprasert, Eng Huat Tan, Michael Smylie and José Rodrigues Pereira and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Vera Hirsh

195 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Frances A. Shepherd, Tudor–Eliade Ciuleanu et al. profile →
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

2009 1.2k citations Martin Reck, Joachim von Pawel et al. Journal of Clinical Oncology profile →
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Vera Hirsh, Tony Mok et al. profile →
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

2011 877 citations Vera Hirsh et al. Journal of Clinical Oncology profile →
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

2012 776 citations Vera Hirsh, Keunchil Park et al. profile →
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Mark A. Socinski, Isamu Okamoto et al. Journal of Clinical Oncology profile →
Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

2003 557 citations Vera Hirsh et al. Journal of Clinical Oncology profile →
Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

2004 507 citations Vera Hirsh et al. profile →
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

2010 498 citations Martin Reck, Joachim von Pawel et al. Annals of Oncology profile →
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

2017 398 citations Luis Paz‐Ares, Kenneth J. O’Byrne et al. Annals of Oncology profile →
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

2013 383 citations Vera Hirsh, Chun‐Ming Tsai et al. profile →

Peers

Countries citing papers authored by Vera Hirsh

Since Specialization

Citations

This map shows the geographic impact of Vera Hirsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vera Hirsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vera Hirsh more than expected).

Fields of papers citing papers by Vera Hirsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vera Hirsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vera Hirsh. The network helps show where Vera Hirsh may publish in the future.

Co-authorship network of co-authors of Vera Hirsh

This figure shows the co-authorship network connecting the top 25 collaborators of Vera Hirsh. A scholar is included among the top collaborators of Vera Hirsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vera Hirsh. Vera Hirsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016 2017 ·Journal of Translational Medicine ·Paolo A. Ascierto, Bruno Daniele, Hans J. Hammers, Vera Hirsh, Joseph W. Kim, Lisa Licitra, Rita Nanda, Sandro Pignata	16
2	P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7 2017 ·Journal of Thoracic Oncology ·Keunchil Park, Eng Huat Tan, Li Zhang, Vera Hirsh, Kenneth J. O’Byrne, Michael Boyer, James Chih‐Hsin Yang, Tony Mok, Barbara Peil, Angela Märten, Luis Paz‐Ares	1
3	P3.02b-023 Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice 2017 ·Journal of Thoracic Oncology ·(unknown), Edward Kim, Matthew Peters, Vera Hirsh	5
4	First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases 2016 ·QUT ePrints (Queensland University of Technology) ·Martin Schüler, Yi‐Long Wu, Vera Hirsh, Kenneth J. O’Byrne, Nobuyuki Yamamoto, Tony Mok, Sanjay Popat, Lecia V. Sequist, Dan Massey, Victoria Zazulina, James Chih‐Hsin Yang	1
5	Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) (Conference Abstract) 2016 ·Annals of Oncology ·Luis Paz‐Ares, (unknown), L. Zhang, Vera Hirsh, Kenneth J. O’Byrne, (unknown)	1
6	138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) 2016 ·Journal of Thoracic Oncology ·Martin Schüler, James Chih‐Hsin Yang, Lecia V. Sequist, Nobuyuki Yamamoto, Caicun Zhou, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Riyaz Shah, Yi‐Long Wu	2
7	P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6 2016 ·Journal of Thoracic Oncology ·Luis Fein, Yi‐Long Wu, Lecia V. Sequist, Sarayut Lucien Geater, Sergey Orlov, Ki Hyeong Lee, Chun‐Ming Tsai, Terufumi Kato, Katsuyuki Kiura, Carlos H. Barrios, Martin Schüler, Vera Hirsh, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Tony Mok, Dan Massey, Angela Märten, James Chih‐Hsin Yang	4
8	440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm +) NSCLC: overall survival (OS) sdata from LUX-Lung 7 (LL7) 2016 ·Annals of Oncology ·K. Park, E.H. Tan, L. Zhang, Vera Hirsh, Kenneth J. O’Byrne, Michael Boyer, James Chih‐Hsin Yang, Tony Mok, (unknown), Shun Lü, Yuankai Shi, Soo Wan Kim, Janessa Laskin, Dongwook Kim, Scott A. Laurie, Karl Kölbeck, Jean Fan, Nigel Dodd, Angela Märten, Luis Paz‐Ares	0
9	Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) 2016 ·Annals of Oncology ·Luis Paz‐Ares, E.H. Tan, L. Zhang, Vera Hirsh, Kenneth J. O’Byrne, Michael Boyer, J.C.-H. Yang, Tony Mok, (unknown), Shun Lü, Yuankai Shi, Soo Wan Kim, Janessa Laskin, Dongwook Kim, Scott A. Laurie, Karl Kölbeck, Jean Fan, Nigel Dodd, Angela Märten, K. Park	9
10	445P Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) 2015 ·Annals of Oncology ·Yi‐Long Wu, Lecia V. Sequist, Martin Schüler, Nobuyuki Yamamoto, C. Zhou, Chengping Hu, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Victoria Zazulina, James Chih‐Hsin Yang	1
11	Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 2014 ·Current Oncology ·Vera Hirsh, Normand Blais, Ronald L. Burkes, Sunil Verma, Kenneth Croitoru	81
12	Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) 2014 ·European Respiratory Journal ·Martin Sebastian, James Chih‐Hsin Yang, Lecia V. Sequist, Martin Schüler, Tony Mok, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Sarayut Lucien Geater, Caicun Zhou, Dan Massey, Victoria Zazulina, Yi‐Long Wu	6
13	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations breakdown → 2013 ·Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler	2461
14	Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer 2013 ·Annals of Oncology ·Mark A. Socinski, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, Nobuyuki Yamamoto, (unknown), Markus F. Renschler	57
15	Phase III Study of Crizotinib vs. Chemotherapy in Advanced ALK+ NSCLC: Patient-Reported Symptoms and Quality of Life 2013 ·Annals of Oncology ·Hiroshi Nokihara, Vera Hirsh, Fiona Blackhall, D.-W. Kim, Benjamin Besse, Ji‐Youn Han, Keith D. Wilner, Arlene Reisman, Shrividya Iyer, A. Shaw	1
16	Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer 2012 ·Annals of Oncology ·Mark A. Socinski, Corey J. Langer, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, (unknown), Markus F. Renschler	92
17	The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials 2010 ·Journal of Thoracic Oncology ·Paul Wheatley‐Price, Aurélie Le Maître, Keyue Ding, Natasha B. Leighl, Vera Hirsh, Lesley Seymour, Andrea Bezjak, Frances A. Shepherd	17
18	B5-02: Radiotherapy volume delineation with PET in lung cancer may be less useful than foreseen 2007 ·Journal of Thoracic Oncology ·Sergio Faria, S. Ménard, Slobodan Dević, Robert Lisbona, Christian Sirois, Vera Hirsh, Luís Souhami, Carolyn Freeman	1
19	C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha B. Leighl, J. Mezger, V.R. Archer, Christian Manegold	6
20	A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial 2004 ·Journal of Clinical Oncology ·Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Ee Hong Tan, Vera Hirsh, S. Thongprasert, Andrea Bezjak, Dongping Tu, (unknown), Lesley Seymour	212

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact